LC-K76 for men with new hormone-sensitive prostate cancer
This trial tests a new drug called LC-K76, made from dandelion extract, in men with prostate cancer that has spread to other parts of the body (metastatic) and is still sensitive to hormone therapy. The goal is to see if adding LC-K76 to standard hormone therapy is safe and helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have been newly diagnosed with prostate cancer that has spread beyond the prostate (to bones or organs) and is still hormone-sensitive.
- You have not received any prior treatment for your prostate cancer.
- You have not had an allergic reaction to dandelion or dandelion products before.
- You are willing to take the study drug (LC-K76 capsules) along with standard hormone therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment for men with advanced prostate cancer that has spread to the bones and stopped responding to standard hormone therapy or chemotherapy. The treatment combines an experimental drug (LC-K76) with a type of immunotherapy (anti-PD-1) that helps your immune system fight cancer.
This trial tests a new drug, HSK46575, for men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy and chemotherapy. The goal is to see if it can help slow the cancer's growth.
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
This trial tests a new drug called HLD-0915 in men with prostate cancer that has spread. It aims to see how well the drug works and if it's safe.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests QLC5508, a new targeted drug for men with metastatic castration-resistant prostate cancer (advanced prostate cancer that has spread and stopped responding to hormone therapy). The drug is designed to work in patients whose cancer has progressed despite prior hormone-based treatments.
Hear when a new mHSPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.